Vir Biotechnology CFO Jason O'Byrne Steps Down; CAO Brent Sabatini Named Interim
VIR has more than doubled off its 52-week low of $4.155.
Summary
Vir Biotechnology's CFO Jason O'Byrne is resigning effective August 3, 2026, to pursue another opportunity. CAO Brent Sabatini will serve as interim principal financial officer while the company searches for a permanent successor.
Key Events · Executive and Board Changes · VIR
-
CFO Departure
CFO Jason O'Byrne resigns effective August 3, 2026, to pursue another opportunity; no disagreement cited.
-
Interim Appointment
CAO Brent Sabatini, a CPA with prior roles at Amgen and Capsida, appointed interim principal financial officer effective August 3, 2026, with no additional compensation.
-
Succession Search Underway
Company has initiated a search for a permanent CFO successor.
Analysis · VIR · Life Sciences
CFO Jason O'Byrne is leaving to pursue another opportunity, effective August 3, 2026. The company says the departure is not due to any disagreement. CAO Brent Sabatini, a CPA with two decades of experience including at Amgen, will serve as interim principal financial officer. No additional compensation is being provided for the interim role. A CFO exit at a $1.6B biotech with a major recent collaboration (Astellas) and a strong cash position ($809M) raises questions about leadership continuity, though the orderly transition and internal successor mitigate immediate disruption risk.
At the time of this filing, VIR was trading at $9.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $4.16 to $11.66. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.